Biotest achieves EBIT forecast for 2023

EQS-News: Biotest AG / Key word(s): Preliminary Results
Biotest achieves EBIT forecast for 2023
29.02.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest achieves EBIT forecast for 2023

• Proposal to this year's Annual General Meeting that preference dividend for the 2023 financial year and the subsequent payment of the preference dividend for the 2022 financial year to be distributed to the preference shareholders.

Dreieich, 29 February 2024: According to preliminary and unaudited figures, EBIT improved significantly in the 2023 financial year to € 143 million after € - 16.6 million in the previous year. The EBIT achieved is therefore in the middle of the forecast range of € 130 million and € 170 million.

In the 2023 financial year, the Biotest Group achieved sales of € 684 million after € 516.1 million in the previous year. This includes the share of sales from the agreement concluded with Grifols on technology disclosure and development services, as well as one-off effects from the change in the scope of consolidation.

The aforementioned preliminary and unaudited figures for the Biotest Group are calculated in accordance with IFRS.

The Management Board and Supervisory Board intend to propose to this year's Annual General Meeting that the preference dividend for the 2023 financial year and the subsequent payment of the preference dividend for the 2022 financial year be distributed to the preference shareholders. Due to an accumulated loss in the 2022 financial year Biotest AG did not pay out any dividends last year.

Biotest will publish the final figures for the 2023 financial year and the annual report on 28 March 2024.

About Biotest

Biotest is a supplier of biological medicinal products derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

29.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com